Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Centessa Pharmaceuticals PLC ADR

Current price
8.1 USD -0.17 USD (-2.06%)
Last closed 8.27 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 934 873 920 USD
Yield for 12 month +77.24 %
21.11.2021 - 28.11.2021

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Address: 1 Ashley Road, Altrincham, United Kingdom, WA14 2DT

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

13.6 USD

P/E ratio

Dividend Yield

Current Year

+6 879 562 USD

Last Year

Current Quarter

Last Quarter

+6 912 614 USD

Current Year

+6 066 423 USD

Last Year

-130 919 USD

Current Quarter

-239 862 USD

Last Quarter

+6 664 475 USD

Key Figures CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -170 972 992 USD
Operating Margin TTM -513.32 %
PE Ratio
Return On Assets TTM -26.61 %
PEG Ratio
Return On Equity TTM -52.79 %
Wall Street Target Price 13.6 USD
Revenue TTM 6 853 000 USD
Book Value 2.39 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -1.42 USD
Diluted Eps TTM -1.42 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CNTA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CNTA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 141.0346
Price Sales TTM 165.6886
Enterprise Value EBITDA -5.8426
Price Book MRQ 4.819

Financials CNTA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CNTA

For 52 weeks

4.3 USD 12.45 USD
50 Day MA 10.11 USD
Shares Short Prior Month 1 793 755
200 Day MA 8.16 USD
Short Ratio 7.04
Shares Short 1 763 646
Short Percent 2.06 %

Dynamics of changes in the value of assets




430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds



14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics



2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics